Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.69 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.69 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.69 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.69 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.62 |
| ▸ | ITGAV | P06756 | 1/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.62 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27543603 | 1.00 | ITGB1 (0.69) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL6561292 | 0.91 | ITGB1 (0.56) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL14799578 | 0.91 | ITGB1 (0.56) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL2880989 | 0.90 | ITGB1 (0.74) | ITGB1ITGA4 | |
| SCHEMBL28833054 | 0.90 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL28833053 | 0.90 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL2987945 | 0.88 | ITGB1 (0.54) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL5225554 | 0.86 | ITGB1 (0.58) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6638467 | 0.85 | ITGB1 (0.63) | ITGB1ITGA4ITGA2ITGB7ITGB3 | |
| SCHEMBL7425167 | 0.85 | ACE (0.55) | ITGB1ITGA4ITGA2ITGB7ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734311-B2 | ANTIINFLAMMATORY AGENTS; ALZHEIMER'S DISEASE; CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2004-05-11 | — | — | US | disclosed |
| EP-1144365-B1 | INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-6685617-B1 | 4-(((-1-CARBOXY-2-(4-((2,6-DICHLOROBENZOYL)AMINE)PHENYL)ETHYL) AMINO)CARBONYL)-3-OXO-3-THIAZOLIDINEBUTANOIC ACID, USED AS ANTAGONISTS FOR CELLULAR ADHESION MOLECULES, AND ADMINISTERED AS ANTIINFLAMMATORY AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-02-03 | — | — | US | disclosed |
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| EP-1144365-A3 | INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-20030092746-A1 | Substituted amidine derivatives as inhibitors of cell adhesion | MERCK & CO., INC. | 2003-05-15 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-6482840-B2 | TREATMENT OF AIDS-RELATED DEMENTIA, ALLERGIC CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, INFLAMMATORY LUNG DISEASES, MENINGITIS, MULTIPLE SCLEROSIS | MERCK & CO., INC. | 2002-11-19 | — | — | US | disclosed |
| US-6420418-B1 | INHIBITION AND PREVENTION OF LEUKOCYTE ADHESION; USED TO TREAT ADHESION-MEDIATED DISEASES SUCH AS ASTHMA, ALLERGIC RHINITIS, MULTIPLE SCLEROSIS; ATHEROSCLEROSIS, AND INFLAMMATORY BOWEL DISEASE | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| US-6403584-B1 | CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, ANTIINFLAMMATORY, ETC | MERCK & CO., INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020010199-A1 | Substituted cyclic amidine derivatives as inhibitors of cell adhesion | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| EP-1144365-A2 | INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
| EP-1089989-A1 | INHIBITORS OF ALPHA4BETA1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2001012183-A1 | HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000037429-A2 | INHIBITORS OF α4β1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
| EP-0991619-A1 | INHIBITORS OF $g(a) 4?$g(b) 1?MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999067230-A1 | INHIBITORS OF α4β1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1998058902-A1 | INHIBITORS OF α4β1MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | ITGB1 3/4885ITGA4 8/4885ITGA2 24/4885 |
| US-20030092746-A1 | Substituted amidine derivatives as inhibitors of cell adhesion | VCAM1, CD4, ICAM1 | ITGB1 9/4885ITGA4 5/4885ITGA2 22/4885 |
| US-20020010199-A1 | Substituted cyclic amidine derivatives as inhibitors of cell adhesion | VCAM1, CD4, ICAM1 | ITGB1 8/4885ITGA4 5/4885ITGA2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.